Syncom Formulations Reports 58% PAT Growth in Q1 FY27

Syncom Formulations (India) Limited announced strong financial results for the first quarter ended June 30, 2026. Consolidated total income grew by 8% to ₹133.36 crore from ₹122.94 crore in the corresponding quarter last year. Profit before tax surged by 59% to ₹332.25 crore, and profit after tax increased by approximately 58% to ₹24.85 crore, up from ₹15.75 crore year-on-year. Earnings per share improved to ₹0.26 from ₹0.17. Revenue from operations saw a nearly 7% increase, reaching ₹125.53 crore. The company's performance is attributed to its ethical, prescription-led model, quality manufacturing, and disciplined cost control. The Board has recommended a final dividend of ₹0.10 per equity share for FY26, subject to shareholder approval.